newsfilter
← Latest News
Business Wire·

Foundation Medicine and its Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic Profiling (CGP) to Inform Targeted and Cancer Immunotherapy Treatment Strategies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the presentation of new findings at the American Association for Cancer Research (AACR) Annual Meeting. The data supports the use of both tissue- and blood-based comprehensive genomic profiling (CGP) to advance personalized cancer care and inform the use of targeted and immunotherapy treatment approaches. Presentations span several of Foundation Medicine’s suite of molecular information products including its recently FDA approved assay, FoundationOne CDx™, as well as FoundationOne®, FoundationACT® and the company’s novel blood-based assay to measure tumor mutational burden (bTMB).